{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-003887","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.508354+00:00","generated_at":"2026-06-04T07:58:19.043919+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aprea Therapeutics reports FY2023 net loss $14.3M ($3.95/share); cash $21.6M; IND cleared for APR-1051","bullets":["Cash and equivalents $21.6M at Dec 31, 2023; combined with $16M Mar 2024 private placement funds into Q3 2025.","Net loss FY2023 $14.3M ($3.95/basic share) vs $112.7M in FY2022 which included $76M acquired IPR&D charge.","ATRN-119 Phase 1/2a dose escalation on track for 4Q 2024 completion; initial efficacy data expected H2 2024.","FDA cleared IND for APR-1051 (WEE1 inhibitor); Phase 1 ACESOT-1051 trial to start H1 2024.","Operating loss $15.5M in FY2023 vs $113.4M in FY2022; R&D expenses fell to $7.6M from $16.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-003887","json":"https://secwatch.observer/filing/0001558370-24-003887.json","markdown":"https://secwatch.observer/filing/0001558370-24-003887.md","text":"https://secwatch.observer/filing/0001558370-24-003887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024003887/0001558370-24-003887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024003887/apre-20240326x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:58:19.043919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}